Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers - 18/08/11
, Heather B. Neuman, M.D., Carolyn Sartor, M.D., Lisa A. Carey, M.D., Nancy Klauber-Demore, M.D.
Corresponding author. University of Chapel Hill, North Carolina, Department of Surgery, Campus Box #7213, 3010 Old Clinic Bldg., Chapel Hill, NC 27599. Tel.: +1-919-966-5221; fax: +1-919-966-8806.Abstract |
Background |
Lymphatic mapping and sentinel lymphadenectomy (LM/SL) accurately evaluates the axilla in patients with small breast cancers. LM/SL in patients with large breast cancers is controversial. We examined the accuracy of LM/SL prior to neoadjuvant chemotherapy in patients with large (>3.5 cm) breast cancers.
Methods |
Patients with large breast cancers underwent LM/SL prior to neoadjuvant chemotherapy using 99m-technetium radiocolloid and isosulfan-blue dye technique.
Results |
Twenty-one patients with large (median 5.0 cm) breast cancers underwent LM/SL prior to neoadjuvant chemotherapy. Twelve patients had a tumor-free sentinel node (SN) and received doxorubicin-based chemotherapy; 9 patients had disease in the SN and received doxorubicin followed by a taxane. No patient progressed while receiving neoadjuvant chemotherapy, nor has there been an axillary recurrence (median 36 months).
Conclusions |
LM/SL performed prior to neoadjuvant chemotherapy in patients with large breast cancers is an accurate method of axillary staging. Axillary staging prior to neoadjuvant chemotherapy may have prognostic and therapeutic implications.
Le texte complet de cet article est disponible en PDF.Keywords : Sentinel lymph node, Neoadjuvant chemotherapy, Large breast cancer
Plan
Vol 190 - N° 3
P. 371-375 - septembre 2005 Retour au numéro
Article précédent
- Is breast cancer sentinel lymph node mapping valuable for patients in their seventies and beyond?
- Lisa E. McMahon, Richard J. Gray, Barbara A. Pockaj
- Presentation, treatment, and multivariate analysis of risk factors for obstructive and perforative colorectal carcinoma
- José Antonio Alvarez, Ricardo F. Baldonedo, Isabel G. Bear, Nuria Truán, Gerardo Pire, Paloma Alvarez
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?